Global Cancer Registry Software Market: Industry Analysis and Forecast (2019-2026), By Type, Deployment model, Database, Functionality, End user and Region.

Market Scenario

Global Cancer Registry Software Market was valued US$ XX Mn in 2019 and is expected to reach US$ 89.90 Mn by 2026, at a CAGR of around XX % during a forecast period. The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region. A cancer registry is a computer based database that uses software solutions to arrange, collect, and store data on cancer patients to evaluate cancer-specific outcomes, conditions, and drug/medical device exposure. These solutions help store, manage, and provide access to information that helps in building a cancer patient registry. The report covers all the trends and technologies playing a major role in the growth of the cancer registry software market during the forecast period. It highlights the drivers, restraints, and opportunities expected to influence market growth during 2019-2026. The global cancer registry software market is being driven by the factors such as the increasing prevalence of cancer, favorable government initiatives, rising pressure to improve the quality of care and reduce healthcare costs, rising adoption of EHRs, and the growing use of cancer patient registry data for post-marketing surveillance are driving the growth of this market. However privacy and data security-related concerns are restricting the market growth. Increase in number of accountable care organizations is creating sufficient opportunities for the market growth. Based on type, standalone software segment is valued at US$ XX Mn in 2018 and is expected to reach US$ XX Mn by 2026 at a CAGR of XX% during the forecast period and accounted for a larger share mainly because of the significant use of standalone software by government organizations & TPAs for population health management which also provides practical and easy-to-use tools to store and process registry data, while standalone software are customized for patient registries, which offers higher flexibility and features such as multiple system usage and automatic up gradation. North America region is expected to grow at XX % rate of CAGR during the forecast period, owing to the innovative product development and increasing investment in research and development for innovation in the region. Furthermore, Europe is expected to hold the second largest position in the global cancer registry software market, due to the presence of strong academic & research base and availability of funding for research in the European countries. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Global cancer registry software Market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in Global Cancer Registry Software Market.

Scope of the Global Cancer Registry Software Market

Global Cancer Registry Software Market, By Type

• Standalone Software • Integrated Software

Global Cancer Registry Software Market, By Deployment model

• On-premise • Cloud-based

Global Cancer Registry Software Market, By Database

• Commercial Databases • Public Databases

Global Cancer Registry Software Market, By Functionality

• Cancer Reporting to Meet State & Federal Regulations • Patient Care Management • Product Outcome Evaluation • Medical Research and Clinical Studies

Global Cancer Registry Software Market, By End user

• Government Organizations & Third-party Administrators (TPAS) • Hospitals & Medical Practices • Pharmaceutical, Biotechnology, & Medical Device Companies • Private Payers • Research Centers

Global Cancer Registry Software Market, By Region

• North America • Europe • Asia Pacific • Middle East & Africa • South America

Key players operating in the Global Cancer Registry Software Market

• Rocky Mountain Cancer Data Systems (RMCDS) • Onco, Inc. • McKesson Corporation • Elekta AB (PUB) • C/Net Solutions • Electronic Registry Systems (ERS), Inc. • ROCKY MOUNTAIN CANCER DATA SYSTEMS • MCKESSON CORPORATION • ORDINAL DATA, INC • CONDUENT, INC • IBM • HIMAGINE SOLUTIONS INC

Table of Contents

Global Cancer Registry Software Market

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Cancer Registry Software Market Size, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Cancer Registry Software Market Analysis and Forecast 6.1. Global Cancer Registry Software Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Cancer Registry Software Market Analysis and Forecast, by Deployment model 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Cancer Registry Software Market Value Share Analysis, by Deployment model 7.4. Global Cancer Registry Software Market Size (US$ Mn) Forecast, by Deployment model 7.5. Global Cancer Registry Software Market Analysis, by Deployment model 7.6. Global Cancer Registry Software Market Attractiveness Analysis, by Deployment model 8. Global Cancer Registry Software Market Analysis and Forecast, by End User 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Cancer Registry Software Market Value Share Analysis, by End User 8.4. Global Cancer Registry Software Market Size (US$ Mn) Forecast, by End User 8.5. Global Cancer Registry Software Market Analysis, by End User 8.6. Global Cancer Registry Software Market Attractiveness Analysis, by End User 9. Global Cancer Registry Software Market Analysis and Forecast, by Type 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Cancer Registry Software Market Value Share Analysis, by Type 9.4. Global Cancer Registry Software Market Size (US$ Mn) Forecast, by Type 9.5. Global Cancer Registry Software Market Analysis, by Type 9.6. Global Cancer Registry Software Market Attractiveness Analysis, by Type 10. Global Cancer Registry Software Market Analysis and Forecast, by Database 10.1. Introduction and Definition 10.2. Key Findings 10.3. Global Cancer Registry Software Market Value Share Analysis, by Database 10.4. Global Cancer Registry Software Market Size (US$ Mn) Forecast, by Database 10.5. Global Cancer Registry Software Market Analysis, by Database 10.6. Global Cancer Registry Software Market Attractiveness Analysis, by Database 11. Global Cancer Registry Software Market Analysis and Forecast, by Functionality 11.1. Introduction and Definition 11.2. Key Findings 11.3. Global Cancer Registry Software Market Value Share Analysis, by Functionality 11.4. Global Cancer Registry Software Market Size (US$ Mn) Forecast, by Functionality 11.5. Global Cancer Registry Software Market Analysis, by Functionality 11.6. Global Cancer Registry Software Market Attractiveness Analysis, by Functionality 12. Global Cancer Registry Software Market Analysis, by Region 12.1. Global Cancer Registry Software Market Value Share Analysis, by Region 12.2. Global Cancer Registry Software Market Size (US$ Mn) Forecast, by Region 12.3. Global Cancer Registry Software Market Attractiveness Analysis, by Region 13. North America Cancer Registry Software Market Analysis 13.1. Key Findings 13.2. North America Cancer Registry Software Market Overview 13.3. North America Cancer Registry Software Market Value Share Analysis, by Deployment model 13.4. North America Cancer Registry Software Market Forecast, by Deployment model 13.4.1. On-premise 13.4.2. Cloud-based 13.5. North America Cancer Registry Software Market Value Share Analysis, by End User 13.6. North America Cancer Registry Software Market Forecast, by End User 13.6.1. Government Organizations & Third-party Administrators (TPAS) 13.6.2. Hospitals & Medical Practices 13.6.3. Pharmaceutical, Biotechnology, & Medical Device Companies 13.6.4. Private Payers 13.6.5. Research Centers 13.7. North America Cancer Registry Software Market Value Share Analysis, by Type 13.8. North America Cancer Registry Software Market Forecast, by Type 13.8.1. Standalone Software 13.8.2. Integrated Software 13.9. North America Cancer Registry Software Market Value Share Analysis, by Database 13.10. North America Cancer Registry Software Market Forecast, by Database 13.10.1. Commercial Databases 13.10.2. Public Databases 13.11. North America Cancer Registry Software Market Value Share Analysis, by Functionality 13.12. North America Cancer Registry Software Market Forecast, by Functionality 13.12.1. Cancer Reporting to Meet State & Federal Regulations 13.12.2. Patient Care Management 13.12.3. Product Outcome Evaluation 13.12.4. Medical Research and Clinical Studies 13.13. North America Cancer Registry Software Market Value Share Analysis, by Country 13.14. North America Cancer Registry Software Market Forecast, by Country 13.14.1. U.S. 13.14.2. Canada 13.15. North America Cancer Registry Software Market Analysis, by Country 13.16. U.S. Cancer Registry Software Market Forecast, by Deployment model 13.16.1. On-premise 13.16.2. Cloud-based 13.17. U.S. Cancer Registry Software Market Forecast, by End User 13.17.1. Government Organizations & Third-party Administrators (TPAS) 13.17.2. Hospitals & Medical Practices 13.17.3. Pharmaceutical, Biotechnology, & Medical Device Companies 13.17.4. Private Payers 13.17.5. Research Centers 13.18. U.S. Cancer Registry Software Market Forecast, by Type 13.18.1. Standalone Software 13.18.2. Integrated Software 13.19. U.S. Cancer Registry Software Market Forecast, by Database 13.19.1. Commercial Databases 13.19.2. Public Databases 13.20. U.S. Cancer Registry Software Market Forecast, by Functionality 13.20.1. Cancer Reporting to Meet State & Federal Regulations 13.20.2. Patient Care Management 13.20.3. Product Outcome Evaluation 13.20.4. Medical Research and Clinical Studies 13.21. Canada Cancer Registry Software Market Forecast, by Deployment model 13.21.1. On-premise 13.21.2. Cloud-based 13.22. Canada Cancer Registry Software Market Forecast, by End User 13.22.1. Government Organizations & Third-party Administrators (TPAS) 13.22.2. Hospitals & Medical Practices 13.22.3. Pharmaceutical, Biotechnology, & Medical Device Companies 13.22.4. Private Payers 13.22.5. Research Centers 13.23. Canada Cancer Registry Software Market Forecast, by Type 13.23.1. Standalone Software 13.23.2. Integrated Software 13.24. Canada Cancer Registry Software Market Forecast, by Database 13.24.1. Commercial Databases 13.24.2. Public Databases 13.25. Canada Cancer Registry Software Market Forecast, by Functionality 13.25.1. Cancer Reporting to Meet State & Federal Regulations 13.25.2. Patient Care Management 13.25.3. Product Outcome Evaluation 13.25.4. Medical Research and Clinical Studies 13.26. North America Cancer Registry Software Market Attractiveness Analysis 13.26.1. By Deployment model 13.26.2. By End User 13.26.3. By Type 13.26.4. By Database 13.26.5. By Functionality 13.27. PEST Analysis 13.28. Key Trends 13.29. Key Developments 14. Europe Cancer Registry Software Market Analysis 14.1. Key Findings 14.2. Europe Cancer Registry Software Market Overview 14.3. Europe Cancer Registry Software Market Value Share Analysis, by Deployment model 14.4. Europe Cancer Registry Software Market Forecast, by Deployment model 14.4.1. On-premise 14.4.2. Cloud-based 14.5. Europe Cancer Registry Software Market Value Share Analysis, by End User 14.6. Europe Cancer Registry Software Market Forecast, by End User 14.6.1. Government Organizations & Third-party Administrators (TPAS) 14.6.2. Hospitals & Medical Practices 14.6.3. Pharmaceutical, Biotechnology, & Medical Device Companies 14.6.4. Private Payers 14.6.5. Research Centers 14.7. Europe Cancer Registry Software Market Value Share Analysis, by Type 14.8. Europe Cancer Registry Software Market Forecast, by Type 14.8.1. Standalone Software 14.8.2. Integrated Software 14.9. Europe Cancer Registry Software Market Value Share Analysis, by Database 14.10. Europe Cancer Registry Software Market Forecast, by Database 14.10.1. Commercial Databases 14.10.2. Public Databases 14.11. Europe Cancer Registry Software Market Value Share Analysis, by Functionality 14.12. Europe Cancer Registry Software Market Forecast, by Functionality 14.12.1. Cancer Reporting to Meet State & Federal Regulations 14.12.2. Patient Care Management 14.12.3. Product Outcome Evaluation 14.12.4. Medical Research and Clinical Studies 14.13. Europe Cancer Registry Software Market Value Share Analysis, by Country 14.14. Europe Cancer Registry Software Market Forecast, by Country 14.14.1. Germany 14.14.2. U.K. 14.14.3. France 14.14.4. Italy 14.14.5. Spain 14.14.6. Rest of Europe 14.15. Europe Cancer Registry Software Market Analysis, by Country 14.16. Germany Cancer Registry Software Market Forecast, by Deployment model 14.16.1. On-premise 14.16.2. Cloud-based 14.17. Germany Cancer Registry Software Market Forecast, by End User 14.17.1. Government Organizations & Third-party Administrators (TPAS) 14.17.2. Hospitals & Medical Practices 14.17.3. Pharmaceutical, Biotechnology, & Medical Device Companies 14.17.4. Private Payers 14.17.5. Research Centers 14.18. Germany Cancer Registry Software Market Forecast, by Type 14.18.1. Standalone Software 14.18.2. Integrated Software 14.19. Germany Cancer Registry Software Market Forecast, by Database 14.19.1. Commercial Databases 14.19.2. Public Databases 14.20. Germany Cancer Registry Software Market Forecast, by Functionality 14.20.1. Cancer Reporting to Meet State & Federal Regulations 14.20.2. Patient Care Management 14.20.3. Product Outcome Evaluation 14.20.4. Medical Research and Clinical Studies 14.21. U.K. Cancer Registry Software Market Forecast, by Deployment model 14.21.1. On-premise 14.21.2. Cloud-based 14.22. U.K. Cancer Registry Software Market Forecast, by End User 14.22.1. Government Organizations & Third-party Administrators (TPAS) 14.22.2. Hospitals & Medical Practices 14.22.3. Pharmaceutical, Biotechnology, & Medical Device Companies 14.22.4. Private Payers 14.22.5. Research Centers 14.23. U.K. Cancer Registry Software Market Forecast, by Type 14.23.1. Standalone Software 14.23.2. Integrated Software 14.24. U.K. Cancer Registry Software Market Forecast, by Database 14.24.1. Commercial Databases 14.24.2. Public Databases 14.25. U.K. Cancer Registry Software Market Forecast, by Functionality 14.25.1. Cancer Reporting to Meet State & Federal Regulations 14.25.2. Patient Care Management 14.25.3. Product Outcome Evaluation 14.25.4. Medical Research and Clinical Studies 14.26. France Cancer Registry Software Market Forecast, by Deployment model 14.26.1. On-premise 14.26.2. Cloud-based 14.27. France Cancer Registry Software Market Forecast, by End User 14.27.1. Government Organizations & Third-party Administrators (TPAS) 14.27.2. Hospitals & Medical Practices 14.27.3. Pharmaceutical, Biotechnology, & Medical Device Companies 14.27.4. Private Payers 14.27.5. Research Centers 14.28. France Cancer Registry Software Market Forecast, by Type 14.28.1. Standalone Software 14.28.2. Integrated Software 14.29. France Cancer Registry Software Market Forecast, by Database 14.29.1. Commercial Databases 14.29.2. Public Databases 14.30. France Cancer Registry Software Market Forecast, by Functionality 14.30.1. Cancer Reporting to Meet State & Federal Regulations 14.30.2. Patient Care Management 14.30.3. Product Outcome Evaluation 14.30.4. Medical Research and Clinical Studies 14.31. Italy Cancer Registry Software Market Forecast, by Deployment model 14.31.1. On-premise 14.31.2. Cloud-based 14.32. Italy Cancer Registry Software Market Forecast, by End User 14.32.1. Government Organizations & Third-party Administrators (TPAS) 14.32.2. Hospitals & Medical Practices 14.32.3. Pharmaceutical, Biotechnology, & Medical Device Companies 14.32.4. Private Payers 14.32.5. Research Centers 14.33. Italy Cancer Registry Software Market Forecast, by Type 14.33.1. Standalone Software 14.33.2. Integrated Software 14.34. Italy Cancer Registry Software Market Forecast, by Database 14.34.1. Commercial Databases 14.34.2. Public Databases 14.35. Italy Cancer Registry Software Market Forecast, by Functionality 14.35.1. Cancer Reporting to Meet State & Federal Regulations 14.35.2. Patient Care Management 14.35.3. Product Outcome Evaluation 14.35.4. Medical Research and Clinical Studies 14.36. Spain Cancer Registry Software Market Forecast, by Deployment model 14.36.1. On-premise 14.36.2. Cloud-based 14.37. Spain Cancer Registry Software Market Forecast, by End User 14.37.1. Government Organizations & Third-party Administrators (TPAS) 14.37.2. Hospitals & Medical Practices 14.37.3. Pharmaceutical, Biotechnology, & Medical Device Companies 14.37.4. Private Payers 14.37.5. Research Centers 14.38. Spain Cancer Registry Software Market Forecast, by Type 14.38.1. Standalone Software 14.38.2. Integrated Software 14.39. Spain Cancer Registry Software Market Forecast, by Database 14.39.1. Commercial Databases 14.39.2. Public Databases 14.40. Spain Cancer Registry Software Market Forecast, by Functionality 14.40.1. Cancer Reporting to Meet State & Federal Regulations 14.40.2. Patient Care Management 14.40.3. Product Outcome Evaluation 14.40.4. Medical Research and Clinical Studies 14.41. Rest of Europe Cancer Registry Software Market Forecast, by Deployment model 14.41.1. On-premise 14.41.2. Cloud-based 14.42. Rest of Europe Cancer Registry Software Market Forecast, by End User 14.42.1. Government Organizations & Third-party Administrators (TPAS) 14.42.2. Hospitals & Medical Practices 14.42.3. Pharmaceutical, Biotechnology, & Medical Device Companies 14.42.4. Private Payers 14.42.5. Research Centers 14.43. Rest of Europe Cancer Registry Software Market Forecast, by Type 14.43.1. Standalone Software 14.43.2. Integrated Software 14.44. Rest Of Europe Cancer Registry Software Market Forecast, by Database 14.44.1. Commercial Databases 14.44.2. Public Databases 14.45. Rest Of Europe Cancer Registry Software Market Forecast, by Functionality 14.45.1. Cancer Reporting to Meet State & Federal Regulations 14.45.2. Patient Care Management 14.45.3. Product Outcome Evaluation 14.45.4. Medical Research and Clinical Studies 14.46. Europe Cancer Registry Software Market Attractiveness Analysis 14.46.1. By Deployment model 14.46.2. By End User 14.46.3. By Type 14.46.4. By Database 14.46.5. By Functionality 14.47. PEST Analysis 14.48. Key Trends 14.49. Key Developments 15. Asia Pacific Cancer Registry Software Market Analysis 15.1. Key Findings 15.2. Asia Pacific Cancer Registry Software Market Overview 15.3. Asia Pacific Cancer Registry Software Market Value Share Analysis, by Deployment model 15.4. Asia Pacific Cancer Registry Software Market Forecast, by Deployment model 15.4.1. On-premise 15.4.2. Cloud-based 15.5. Asia Pacific Cancer Registry Software Market Value Share Analysis, by End User 15.6. Asia Pacific Cancer Registry Software Market Forecast, by End User 15.6.1. Government Organizations & Third-party Administrators (TPAS) 15.6.2. Hospitals & Medical Practices 15.6.3. Pharmaceutical, Biotechnology, & Medical Device Companies 15.6.4. Private Payers 15.6.5. Research Centers 15.7. Asia Pacific Cancer Registry Software Market Value Share Analysis, by Type 15.8. Asia Pacific Cancer Registry Software Market Forecast, by Type 15.8.1. Standalone Software 15.8.2. Integrated Software 15.9. Asia Pacific Cancer Registry Software Market Value Share Analysis, by Database 15.10. Asia Pacific Cancer Registry Software Market Forecast, by Database 15.10.1. Commercial Databases 15.10.2. Public Databases 15.11. Asia Pacific Cancer Registry Software Market Value Share Analysis, by Functionality 15.12. Asia Pacific Cancer Registry Software Market Forecast, by Functionality 15.12.1. Cancer Reporting to Meet State & Federal Regulations 15.12.2. Patient Care Management 15.12.3. Product Outcome Evaluation 15.12.4. Medical Research and Clinical Studies 15.13. Asia Pacific Cancer Registry Software Market Value Share Analysis, by Country 15.14. Asia Pacific Cancer Registry Software Market Forecast, by Country 15.14.1. China 15.14.2. India 15.14.3. Japan 15.14.4. ASEAN 15.14.5. Rest of Asia Pacific 15.15. Asia Pacific Cancer Registry Software Market Analysis, by Country 15.16. China Cancer Registry Software Market Forecast, by Deployment model 15.16.1. On-premise 15.16.2. Cloud-based 15.17. China Cancer Registry Software Market Forecast, by End User 15.17.1. Government Organizations & Third-party Administrators (TPAS) 15.17.2. Hospitals & Medical Practices 15.17.3. Pharmaceutical, Biotechnology, & Medical Device Companies 15.17.4. Private Payers 15.17.5. Research Centers 15.18. China Cancer Registry Software Market Forecast, by Type 15.18.1. Standalone Software 15.18.2. Integrated Software 15.19. China Cancer Registry Software Market Forecast, by Database 15.19.1. Commercial Databases 15.19.2. Public Databases 15.20. China Cancer Registry Software Market Forecast, by Functionality 15.20.1. Cancer Reporting to Meet State & Federal Regulations 15.20.2. Patient Care Management 15.20.3. Product Outcome Evaluation 15.20.4. Medical Research and Clinical Studies 15.21. India Cancer Registry Software Market Forecast, by Deployment model 15.21.1. On-premise 15.21.2. Cloud-based 15.22. India Cancer Registry Software Market Forecast, by End User 15.22.1. Government Organizations & Third-party Administrators (TPAS) 15.22.2. Hospitals & Medical Practices 15.22.3. Pharmaceutical, Biotechnology, & Medical Device Companies 15.22.4. Private Payers 15.22.5. Research Centers 15.23. India Cancer Registry Software Market Forecast, by Type 15.23.1. Standalone Software 15.23.2. Integrated Software 15.24. India Cancer Registry Software Market Forecast, by Database 15.24.1. Commercial Databases 15.24.2. Public Databases 15.25. India Cancer Registry Software Market Forecast, by Functionality 15.25.1. Cancer Reporting to Meet State & Federal Regulations 15.25.2. Patient Care Management 15.25.3. Product Outcome Evaluation 15.25.4. Medical Research and Clinical Studies 15.26. Japan Cancer Registry Software Market Forecast, by Deployment model 15.26.1. On-premise 15.26.2. Cloud-based 15.27. Japan Cancer Registry Software Market Forecast, by End User 15.27.1. Government Organizations & Third-party Administrators (TPAS) 15.27.2. Hospitals & Medical Practices 15.27.3. Pharmaceutical, Biotechnology, & Medical Device Companies 15.27.4. Private Payers 15.27.5. Research Centers 15.28. Japan Cancer Registry Software Market Forecast, by Type 15.28.1. Standalone Software 15.28.2. Integrated Software 15.29. Japan Cancer Registry Software Market Forecast, by Database 15.29.1. Commercial Databases 15.29.2. Public Databases 15.30. Japan Cancer Registry Software Market Forecast, by Functionality 15.30.1. Cancer Reporting to Meet State & Federal Regulations 15.30.2. Patient Care Management 15.30.3. Product Outcome Evaluation 15.30.4. Medical Research and Clinical Studies 15.31. ASEAN Cancer Registry Software Market Forecast, by Deployment model 15.31.1. On-premise 15.31.2. Cloud-based 15.32. ASEAN Cancer Registry Software Market Forecast, by End User 15.32.1. Government Organizations & Third-party Administrators (TPAS) 15.32.2. Hospitals & Medical Practices 15.32.3. Pharmaceutical, Biotechnology, & Medical Device Companies 15.32.4. Private Payers 15.32.5. Research Centers 15.33. ASEAN Cancer Registry Software Market Forecast, by Type 15.33.1. Standalone Software 15.33.2. Integrated Software 15.34. ASEAN Cancer Registry Software Market Forecast, by Database 15.34.1. Commercial Databases 15.34.2. Public Databases 15.35. ASEAN Cancer Registry Software Market Forecast, by Functionality 15.35.1. Cancer Reporting to Meet State & Federal Regulations 15.35.2. Patient Care Management 15.35.3. Product Outcome Evaluation 15.35.4. Medical Research and Clinical Studies 15.36. Rest of Asia Pacific Cancer Registry Software Market Forecast, by Deployment model 15.36.1. On-premise 15.36.2. Cloud-based 15.37. Rest of Asia Pacific Cancer Registry Software Market Forecast, by End User 15.37.1. Government Organizations & Third-party Administrators (TPAS) 15.37.2. Hospitals & Medical Practices 15.37.3. Pharmaceutical, Biotechnology, & Medical Device Companies 15.37.4. Private Payers 15.37.5. Research Centers 15.38. Rest of Asia Pacific Cancer Registry Software Market Forecast, by Type 15.38.1. Standalone Software 15.38.2. Integrated Software 15.39. Rest of Asia Pacific Cancer Registry Software Market Forecast, by Database 15.39.1. Commercial Databases 15.39.2. Public Databases 15.40. Rest of Asia Pacific Cancer Registry Software Market Forecast, by Functionality 15.40.1. Cancer Reporting to Meet State & Federal Regulations 15.40.2. Patient Care Management 15.40.3. Product Outcome Evaluation 15.40.4. Medical Research and Clinical Studies 15.41. Asia Pacific Cancer Registry Software Market Attractiveness Analysis 15.41.1. By Deployment model 15.41.2. By End User 15.41.3. By Type 15.41.4. By Database 15.41.5. By Functionality 15.42. PEST Analysis 15.43. Key Trends 15.44. Key Developments 16. Middle East & Africa Cancer Registry Software Market Analysis 16.1. Key Findings 16.2. Middle East & Africa Cancer Registry Software Market Overview 16.3. Middle East & Africa Cancer Registry Software Market Value Share Analysis, by Deployment model 16.4. Middle East & Africa Cancer Registry Software Market Forecast, by Deployment model 16.4.1. On-premise 16.4.2. Cloud-based 16.5. Middle East & Africa Cancer Registry Software Market Value Share Analysis, by End User 16.6. Middle East & Africa Cancer Registry Software Market Forecast, by End User 16.6.1. Government Organizations & Third-party Administrators (TPAS) 16.6.2. Hospitals & Medical Practices 16.6.3. Pharmaceutical, Biotechnology, & Medical Device Companies 16.6.4. Private Payers 16.6.5. Research Centers 16.7. Middle East & Africa Cancer Registry Software Market Value Share Analysis, by Type 16.8. Middle East & Africa Cancer Registry Software Market Forecast, by Type 16.8.1. Standalone Software 16.8.2. Integrated Software 16.9. Middle East & Africa Cancer Registry Software Market Value Share Analysis, by Database 16.10. Middle East & Africa Cancer Registry Software Market Forecast, by Database 16.10.1. Commercial Databases 16.10.2. Public Databases 16.11. Middle East & Africa Cancer Registry Software Market Value Share Analysis, by Functionality 16.12. Middle East & Africa Cancer Registry Software Market Forecast, by Functionality 16.12.1. Cancer Reporting to Meet State & Federal Regulations 16.12.2. Patient Care Management 16.12.3. Product Outcome Evaluation 16.12.4. Medical Research and Clinical Studies 16.13. Middle East & Africa Cancer Registry Software Market Value Share Analysis, by Country 16.14. Middle East & Africa Cancer Registry Software Market Forecast, by Country 16.14.1. GCC 16.14.2. South Africa 16.14.3. Rest of Middle East & Africa 16.15. Middle East & Africa Cancer Registry Software Market Analysis, by Country 16.16. GCC Cancer Registry Software Market Forecast, by Deployment model 16.16.1. On-premise 16.16.2. Cloud-based 16.17. GCC Cancer Registry Software Market Forecast, by End User 16.17.1. Government Organizations & Third-party Administrators (TPAS) 16.17.2. Hospitals & Medical Practices 16.17.3. Pharmaceutical, Biotechnology, & Medical Device Companies 16.17.4. Private Payers 16.17.5. Research Centers 16.18. GCC Cancer Registry Software Market Forecast, by Type 16.18.1. Standalone Software 16.18.2. Integrated Software 16.19. GCC Cancer Registry Software Market Forecast, by Database 16.19.1. Commercial Databases 16.19.2. Public Databases 16.20. GCC Cancer Registry Software Market Forecast, by Functionality 16.20.1. Cancer Reporting to Meet State & Federal Regulations 16.20.2. Patient Care Management 16.20.3. Product Outcome Evaluation 16.20.4. Medical Research and Clinical Studies 16.21. South Africa Cancer Registry Software Market Forecast, by Deployment model 16.21.1. On-premise 16.21.2. Cloud-based 16.22. South Africa Cancer Registry Software Market Forecast, by End User 16.22.1. Government Organizations & Third-party Administrators (TPAS) 16.22.2. Hospitals & Medical Practices 16.22.3. Pharmaceutical, Biotechnology, & Medical Device Companies 16.22.4. Private Payers 16.22.5. Research Centers 16.23. South Africa Cancer Registry Software Market Forecast, by Type 16.23.1. Standalone Software 16.23.2. Integrated Software 16.24. South Africa Cancer Registry Software Market Forecast, by Database 16.24.1. Commercial Databases 16.24.2. Public Databases 16.25. South Africa Cancer Registry Software Market Forecast, by Functionality 16.25.1. Cancer Reporting to Meet State & Federal Regulations 16.25.2. Patient Care Management 16.25.3. Product Outcome Evaluation 16.25.4. Medical Research and Clinical Studies 16.26. Rest of Middle East & Africa Cancer Registry Software Market Forecast, by Deployment model 16.26.1. On-premise 16.26.2. Cloud-based 16.27. Rest of Middle East & Africa Cancer Registry Software Market Forecast, by End User 16.27.1. Government Organizations & Third-party Administrators (TPAS) 16.27.2. Hospitals & Medical Practices 16.27.3. Pharmaceutical, Biotechnology, & Medical Device Companies 16.27.4. Private Payers 16.27.5. Research Centers 16.28. Rest of Middle East & Africa Cancer Registry Software Market Forecast, by Type 16.28.1. Standalone Software 16.28.2. Integrated Software 16.29. Rest of Middle East & Africa Cancer Registry Software Market Forecast, by Database 16.29.1. Commercial Databases 16.29.2. Public Databases 16.30. Rest of Middle East & Africa Cancer Registry Software Market Forecast, by Functionality 16.30.1. Cancer Reporting to Meet State & Federal Regulations 16.30.2. Patient Care Management 16.30.3. Product Outcome Evaluation 16.30.4. Medical Research and Clinical Studies 16.31. Middle East & Africa Cancer Registry Software Market Attractiveness Analysis 16.31.1. By Deployment model 16.31.2. By End User 16.31.3. By Type 16.31.4. By Database 16.31.5. By Functionality 16.32. PEST Analysis 16.33. Key Trends 16.34. Key Developments 17. South America Cancer Registry Software Market Analysis 17.1. Key Findings 17.2. South America Cancer Registry Software Market Overview 17.3. South America Cancer Registry Software Market Value Share Analysis, by Deployment model 17.4. South America Cancer Registry Software Market Forecast, by Deployment model 17.4.1. On-premise 17.4.2. Cloud-based 17.5. South America Cancer Registry Software Market Value Share Analysis, by End User 17.6. South America Cancer Registry Software Market Forecast, by End User 17.6.1. Government Organizations & Third-party Administrators (TPAS) 17.6.2. Hospitals & Medical Practices 17.6.3. Pharmaceutical, Biotechnology, & Medical Device Companies 17.6.4. Private Payers 17.6.5. Research Centers 17.7. South America Cancer Registry Software Market Value Share Analysis, by Type 17.8. South America Cancer Registry Software Market Forecast, by Type 17.8.1. Standalone Software 17.8.2. Integrated Software 17.9. South America Cancer Registry Software Market Value Share Analysis, by Database 17.10. South America Cancer Registry Software Market Forecast, by Database 17.10.1. Commercial Databases 17.10.2. Public Databases 17.11. South America Cancer Registry Software Market Value Share Analysis, by Functionality 17.12. South America Cancer Registry Software Market Forecast, by Functionality 17.12.1. Cancer Reporting to Meet State & Federal Regulations 17.12.2. Patient Care Management 17.12.3. Product Outcome Evaluation 17.12.4. Medical Research and Clinical Studies 17.13. South America Cancer Registry Software Market Value Share Analysis, by Country 17.14. South America Cancer Registry Software Market Forecast, by Country 17.14.1. Brazil 17.14.2. Mexico 17.14.3. Rest of South America 17.15. South America Cancer Registry Software Market Analysis, by Country 17.16. Brazil Cancer Registry Software Market Forecast, by Deployment model 17.16.1. On-premise 17.16.2. Cloud-based 17.17. Brazil Cancer Registry Software Market Forecast, by End User 17.17.1. Government Organizations & Third-party Administrators (TPAS) 17.17.2. Hospitals & Medical Practices 17.17.3. Pharmaceutical, Biotechnology, & Medical Device Companies 17.17.4. Private Payers 17.17.5. Research Centers 17.18. Brazil Cancer Registry Software Market Forecast, by Type 17.18.1. Standalone Software 17.18.2. Integrated Software 17.19. Brazil Cancer Registry Software Market Forecast, by Database 17.19.1. Commercial Databases 17.19.2. Public Databases 17.20. Brazil Cancer Registry Software Market Forecast, by Functionality 17.20.1. Cancer Reporting to Meet State & Federal Regulations 17.20.2. Patient Care Management 17.20.3. Product Outcome Evaluation 17.20.4. Medical Research and Clinical Studies 17.21. Mexico Cancer Registry Software Market Forecast, by Deployment model 17.21.1. On-premise 17.21.2. Cloud-based 17.22. Mexico Cancer Registry Software Market Forecast, by End User 17.22.1. Government Organizations & Third-party Administrators (TPAS) 17.22.2. Hospitals & Medical Practices 17.22.3. Pharmaceutical, Biotechnology, & Medical Device Companies 17.22.4. Private Payers 17.22.5. Research Centers 17.23. Mexico Cancer Registry Software Market Forecast, by Type 17.23.1. Standalone Software 17.23.2. Integrated Software 17.24. Mexico Cancer Registry Software Market Forecast, by Database 17.24.1. Commercial Databases 17.24.2. Public Databases 17.25. Mexico Cancer Registry Software Market Forecast, by Functionality 17.25.1. Cancer Reporting to Meet State & Federal Regulations 17.25.2. Patient Care Management 17.25.3. Product Outcome Evaluation 17.25.4. Medical Research and Clinical Studies 17.26. Rest of South America Cancer Registry Software Market Forecast, by Deployment model 17.26.1. On-premise 17.26.2. Cloud-based 17.27. Rest of South America Cancer Registry Software Market Forecast, by End User 17.27.1. Government Organizations & Third-party Administrators (TPAS) 17.27.2. Hospitals & Medical Practices 17.27.3. Pharmaceutical, Biotechnology, & Medical Device Companies 17.27.4. Private Payers 17.27.5. Research Centers 17.28. Rest of South America Cancer Registry Software Market Forecast, by Type 17.28.1. Standalone Software 17.28.2. Integrated Software 17.29. Rest of South America Cancer Registry Software Market Forecast, by Database 17.29.1. Commercial Databases 17.29.2. Public Databases 17.30. Rest of South America Cancer Registry Software Market Forecast, by Functionality 17.30.1. Cancer Reporting to Meet State & Federal Regulations 17.30.2. Patient Care Management 17.30.3. Product Outcome Evaluation 17.30.4. Medical Research and Clinical Studies 17.31. South America Cancer Registry Software Market Attractiveness Analysis 17.31.1. By Deployment model 17.31.2. By End User 17.31.3. By Type 17.31.4. By Database 17.31.5. By Functionality 17.32. PEST Analysis 17.33. Key Trends 17.34. Key Developments 18. Company Profiles 18.1. Market Share Analysis, by Company 18.2. Competition Matrix 18.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 18.2.2. New Product Launches and Product Enhancements 18.2.3. Market Consolidation 18.2.3.1. M&A by Regions, Investment and Applications 18.2.3.2. M&A Key Players, Forward Integration and Backward Integration 18.3. Company Profiles: Key Players 18.3.1. Rocky Mountain Cancer Data Systems (RMCDS) 18.3.1.1. Company Overview 18.3.1.2. Financial Overview 18.3.1.3. Product Portfolio 18.3.1.4. Business Strategy 18.3.1.5. Recent Developments 18.3.1.6. Company Footprint 18.3.2. Onco, Inc. 18.3.3. McKesson Corporation 18.3.4. Elekta AB (PUB) 18.3.5. C/Net Solutions 18.3.6. Electronic Registry Systems (ERS), Inc. 18.3.7. ROCKY MOUNTAIN CANCER DATA SYSTEMS 18.3.8. MCKESSON CORPORATION 18.3.9. ORDINAL DATA, INC 18.3.10. CONDUENT, INC 18.3.11. IBM 18.3.12. HIMAGINE SOLUTIONS INC 19. Primary Key Insights

About This Report

Report ID 34009
Category Information Technology & Telecommunication
Published Date Sept 2019
No of Pages 235
Contact Us